

From Academia to Community Care: Lessons Learned and Considerations for Delivering Excellent Care

Ashley E. Ross, M.D., Ph.D.

Texas Urology Specialists, Texas Oncology

US Oncology GU Committee Associate Chair

Executive Director, Mary Crowley Cancer Research Center



Academia Versus Private Practice

ACADEMIA

- Properties
 - Focus on discovery / development of new technologies; education of trainees
 - Key question – what is the best next standard of care?
- Strengths
 - Name recognition
 - Consolidated care
 - Experts / key opinion leaders in many fields
- Weaknesses
 - Limitations on collaboration with industry
 - *Often favor "home grown" products or investigator initiated trials which are not necessarily better*
 - Intra and inter institutional collaboration can be limited
 - *Operationalizing technologies can be limited*
 - *Bureaucracy, egos, competing interests*
 - Episodic care can pose a challenge for care continuity



PRIVATE

- Properties
 - Focus on patient care and implementation of proven technologies
 - Key question – how do I provide the best care for my patients?
- Strengths
 - Focus on the patient and efficiency
 - Operationalization of technologies more streamlined
 - Industry collaboration
 - *More freedom to implement what the group deems the best product / technology*
 - Easier access to care / care continuity
- Weaknesses
 - Limited guidance on finding the best MDs / practices and higher variance between practices and within practices
 - Multi-disciplinary care / facilities often not under one roof
 - More limited access to emerging or unproven, but promising, technologies

Operationalizing a Premiere Prostate Cancer Practice in the Community Setting




- Requires capitalizing on the strengths of private practice
- Protocols and technologies implemented to routinely augment diagnosis and treatment
- Few anecdotes for today –
 - Digital pathology with spatial orientation
 - Protocol driven IHC and molecular testing
 - Clinical trial matching

Digital Pathology with Spatial Orientation -- Lumea





BxChip

The BxChip is an artificially-engineered tissue array that holds up to 6 needle-core biopsies to be processed in a single block.





- › 73% decrease in laboratory time (grossing, embedding, sectioning)
- › 13% increase in tissue length
- › 37% decrease in pathology diagnostic time
- › Standardizes tissue handling for AI development



- › Simplified diagnostic process - circle and grade cancerous lesions
- › Digital diagnostic review and reporting across multiple digital platforms (beta testing AI on H+E)
- › AI assisted diagnosis: tissue detection, diagnostic calculations and report generation

Protocol Driven Molecular Testing (GG1-2)

Protocol Impact- Increased Utilization of Prolaris, Leading to Improved Risk Stratification




Clinical Trial Matching -- TEMPUS

GENOMIC VARIANTS

Somatic - Potentially Actionable

Variant Allele Fraction



CLINICAL TRIALS

ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations ([NCT02761694](#))

Phase I
Oklahoma City, OK - 171 mi
✓ **PIK3CA mutation**
✓ **PTEN deletion**

To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer ([NCT03006172](#))

Phase I
Nashville, TN - 609 mi
✓ **PIK3CA mutation**

Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies ([NCT03209401](#))

Phase I
Washington, District of Columbia - 1174 mi
✓ **ATRX mutation**
✓ **PTEN deletion**


Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors ([NCT03065062](#))

Phase I
Boston, MA - 1539 mi
✓ **PIK3CA mutation**

Clinical Trial Matching – Mary Crowley

iPhone APP: A Referral Tool

- Search Clinical Trials by Disease Type or Molecular Target
- Speak Directly with our Research Coordinator within in the App
- Receive Instant Notifications of NEW Clinical Trial Openings





Thanks!
Questions?